BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 17155868)

  • 1. Tissue-specific compartmental analysis for dynamic contrast-enhanced MR imaging of complex tumors.
    Chen L; Choyke PL; Chan TH; Chi CY; Wang G; Wang Y
    IEEE Trans Med Imaging; 2011 Dec; 30(12):2044-58. PubMed ID: 21708498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the Tumor Microenvironment and Tumor-Stroma Interaction by Non-invasive Preclinical Imaging.
    Ramamonjisoa N; Ackerstaff E
    Front Oncol; 2017; 7():3. PubMed ID: 28197395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiparametric MR Imaging in Abdominal Malignancies.
    Luna A; Pahwa S; Bonini C; Alcalá-Mata L; Wright KL; Gulani V
    Magn Reson Imaging Clin N Am; 2016 Feb; 24(1):157-186. PubMed ID: 26613880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anatomical, Physiological, and Molecular Imaging for Pancreatic Cancer: Current Clinical Use and Future Implications.
    Chang J; Schomer D; Dragovich T
    Biomed Res Int; 2015; 2015():269641. PubMed ID: 26146615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tracer kinetics analysis of dynamic contrast-enhanced CT and MR data in patients with squamous cell carcinoma of the upper aerodigestive tract: comparison of the results.
    Bisdas S; Baghi M; Wagenblast J; Bisdas T; Thng CH; Mack MG; Koh TS; Ernemann U
    Clin Physiol Funct Imaging; 2009 Sep; 29(5):339-46. PubMed ID: 19473200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reproducibility of the aortic input function (AIF) derived from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) of the kidneys in a volunteer study.
    Mendichovszky IA; Cutajar M; Gordon I
    Eur J Radiol; 2009 Sep; 71(3):576-81. PubMed ID: 19004588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On the a priori identifiability of the two-compartment distributed parameter model from residual tracer data acquired by dynamic contrast-enhanced imaging.
    Koh TS
    IEEE Trans Biomed Eng; 2008 Jan; 55(1):340-4. PubMed ID: 18232378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A method for pharmacokinetic modelling of dynamic contrast enhanced MRI studies of rapidly enhancing lesions acquired in a clinical setting.
    Radjenovic A; Ridgway JP; Smith MA
    Phys Med Biol; 2006 May; 51(9):N187-97. PubMed ID: 16625029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic MR-mammography in virtual reality.
    Englmeier KH; Hellwig G; Griebel J; Delorme S; Siebert M; Brix G
    Stud Health Technol Inform; 2003; 94():72-8. PubMed ID: 15455867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tracer kinetic analysis of signal time series from dynamic contrast-enhanced MR imaging.
    Brix G; Lucht R; Griebel J
    Biomed Tech (Berl); 2006 Dec; 51(5-6):325-30. PubMed ID: 17155868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic contrast-enhanced breast MR imaging.
    Moon M; Cornfeld D; Weinreb J
    Magn Reson Imaging Clin N Am; 2009 May; 17(2):351-62. PubMed ID: 19406363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Methodological approaches to quantitative evaluation of microcirculation in tissues with dynamic magnetic resonance tomography].
    Brix G; Schreiber W; Hoffmann U; Gückel F; Hawighorst H; Knopp MV
    Radiologe; 1997 Jun; 37(6):470-80. PubMed ID: 9340677
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.